|
Motion Sickness:
A Review of Its Cause and Pharmacological and Nonpharmacological Therapies
INTRODUCTION
Motion sickness can occur when the
sensory inputs about body position contradict what is expected. It can be provoked by
abrupt changes in movement, such as occur during bumpy rides, turbulent flights, and rough
seas. It can also occur when one is exposed to moving visual scenes while the body is in a
relatively fixed state.
Early signs of motion sickness include
pallor, restlessness, and cold sweat. In later stages, nausea, excessive salivating, and
vomiting occur.(1) The degree of symptoms that result from an acute exposure to
provocative stimuli vary with the intensity of the stimulus and one's susceptibility to
this condition.
About one third of the population is
highly susceptible to motion sickness, a third experience it in fairly rough conditions,
and another third become sick only in extreme conditions.(1) Selected groups seem
particularly susceptible, including children aged 3 to 12 years (2), people who experience
migraine headaches (3), and women, particularly during menstruation and pregnancy.(3, 4)
This paper provides an overview of the
theories regarding the etiology of motion sickness and reviews currently available
treatments, including nonpharmacological remedies, over-the-counter products, and
prescriptive-strength medications.
ETIOLOGY OF MOTION SICKNESS
The precise etiology of motion remains
a mystery. The classic "sensory conflict" explanation, posed by Reason and Brand
and supported by subsequent studies, suggests motion sickness is triggered when the brain
interprets sensory messages regarding movement as inharmonious. (5) These messages are
delivered by the parts of the body that detect motion, including the vestibular receptors,
the eyes, and proprioceptors in the skin, muscles, and other tissues. Sometimes the
incoming signals from these sensory sites conflict with each other; other times these
signals conflict with the brain's "positional memory".
The traditional sensory conflict
theory does not explain motion sickness produced by all conditions, however. For instance,
it is unclear why passive low-frequency vertical linear acceleration can cause nausea in
humans.(6) Thus, additional sensory inputs other than those traditionally are thought to
trigger motion sickness may play some role. Mittelstaedt, for instance, recently
introduced evidence suggesting inputs from visceral graviceptors may contribute to how the
body determines its position.(7, 8)
Another new theory for some cases of
motion sickness is the postural instability theory, based on experiments in which motion
sickness was preceded by statistically significant increases in several indices of
postural sway. In these cases, motion sickness symptoms were not linked to sensory
conflict, but rather to a decreased ability to actively control the body's postural
motion.
ANTIMOTION SICKNESS TREATMENTS
A variety of antimotion sickness
treatments are available which can protect most people if taken one to two hours prior to
exposure and in sufficient dosage.(9)
Most nonpharmacologic remedies
currently available for motion sickness are not supported by scientific evidence of
efficacy, although new therapies are currently under investigation.
Ingesting large amounts of ginger has
long been touted as a cure, but there is little more than anecdotal accounts of any real
benefit, although this herb could induce some placebo effect in individuals who experience
motion sickness due primarily to psychological factors.(9)
Using acupressure to activate the P6
pressure point above the wrist has been shown to effectively combat nausea and vomiting
associated with chemotherapy, pregnancy, and surgery (10), but it has shown little
effectiveness for motion sickness. The use of popular acupressure bands (SeaBands), which
are worn around the wrist to apply pressure to the P6 point, also showed no benefit for
combating motion sickness. (11, 12)
Some preliminary evidence suggests
that electrically stimulating this point may provide some benefit, however. Hu et al found
that the severity of motion sickness symptoms could be reduced by placing cutaneous
electrodes over the P6 point. (13) In another small study of nine people, Bertolluci et al
noted that wearing a portable wristwatch size device that allows them to electrically
stimulate the P6 point showed some effectiveness. (14) Continued research on this seems
warranted for treating mild cases of motion sickness, although the cost of this treatment
could be a drawback for many candidates.
Psychological therapies have also been
investigated. Biofeedback does little to reduce symptoms or to increase tolerance to
motion (11, 15). Cognitive behavioral training can help to build some tolerance to
provocative motion stimuli and to reduce the need for antimotion medications, but the
process is quite time-consuming and thus impractical for most people.(16)
One interesting study reported a
significant decrease in vomiting episodes among 201 children, reportedly prone to motion
sickness, when they wore prism glasses that had been prescribed to improve their
mechanical reading skills. These glasses are typically worn by children with learning
disabilities or Meniere's disease. The prism glasses are thought to decrease discrepancy
between visual and vestibular cues and thus to reduce the negative effects of vertigo.(17)
Again, further study on their usefulness in treating motion sickness seems warranted.
PHARMACOLOGIC TREATMENTS
Two classes of drugs are known to be
effective against motion sickness: those that are central cholinergic blockers and those
that enhance dopamine-norepinephrine activity. These drugs act on various sites, including
the vestibular receptors and nuclei, the cerebellum, the reticular area, and the vomiting
center. All antimotion medications are also effective antiemetic agents. (1)
Researchers at the Naval Aerospace
Medical Institute in Florida offer the following theory of how these agents work (18): the
central nervous system reacts to provocative motion stimuli and, in turn, vestibular
impulses are transmitted to the vestibular nuclei, the cerebellum, and the brain stem
reticular areas. In the vestibular nuclei and the reticular areas, neurons that are
responsive to noradrenaline intermingle with those responsive to acetylcholine. These two
neural populations appear to compete against each other. Those mediated by acetylcholine
increase activity with vestibular stimulation and release a "neurotransmitter
signal" which activates the vomiting center. Neurons responding to the noradrenaline
promote stabilization, which staves off motion sickness. Some of the effective drugs block
acetylcholine while others activate noradrenaline. The balance between these two neuron
groups could be influenced by medications and would govern a person's susceptibility to
motion sickness. The proper use of motion sickness drugs, then, could ensure that the
balance remains favorable for the patient.
Cholinergic blockers include
scopolamine, atropine, dimenhydrinate, cyclizine, meclizine, and promethazine. (9) The
effective sympathomimetics include d-amphetamine, methamphetamine, premoline,
phenmetrazine, phenemine, and methylphanidate.(19)
These drugs are available in a variety
of forms including oral, intramuscular, and suppositories. Drugs taken orally must be
taken in a sufficient dosage at least an hour in advance to be effective; otherwise, they
must be administered intramuscularly in most cases if motion sickness symptoms have
already surfaced. (9)
OTC MEDICINES
Over-the-counter remedies are less
effective than prescription-strength medications, but provide a lesser degree of side
effects and long duration of 6 to 12 hours. (20). These must be taken at least an hour
before exposure to be effective, since gastric motility decrease following the onset of
motion sickness.(9) These can be useful for travelers who experience mild to moderate
cases of motion sickness. Most of these (remedy) medications are antihistamines, and their
initial use stemmed from reports that people being treated for allergies also experienced
fewer problems with motion sickness. Although it is unclear precisely how they work to
suppress motion sickness symptoms, their anticholinergic properties appear to be the
important element.(21)
Anecdotal reports indicate large
individual differences in the effectiveness of antihistamines as antimotion sickness
drugs. Dimenhydrinate (Dramamine) appears to be the most effective. The usual adult dosage
is 50 mg, which typically produces some drowsiness and minor dizziness. (9) It is not
recommended when driving or working around machinery, but can be a good choice for long
exposure to mild-to-moderate motion.(18)
Cyclizine (Marezine) is somewhat less
effective at the usual adult dosage of 50 mg, but causes less drowsiness and dizziness and
is often used to avoid travel sickness in children or very mild short-term exposures to
motion in adults. (9) When Weinstein et al compared cyclizine and dimenhydrinate in a
study involving 5 college students deemed susceptible to motion sickness, they found that
the two are similarly effective in preventing the overall subjective symptoms of motion
sickness, such as dizziness, sweating, and nausea. Marezine, however, was associated with
more improvement of GI symptoms and with significantly less drowsiness than dramamine 30
minutes after ingestion (22, 23)
Meclizine (Bonine, Antivert) has a
slower onset and longer duration (12 to 24 hours) of action than the other antihistamines.
The slower onset may be why it also has a lower efficacy rating. Side effects include
drowsiness, dry mouth, blurred vision, and dizziness. (9)
PRESCRIPTION MEDICINES
Scopolamine
Scopolamine is the single most
effective antimotion sickness drug, consistently providing more protection than any other
single medication in clinical trials.(9) It is particularly useful for intense motion or
for patients who are very susceptible to motion sickness remedy.
Scopolamine is a belladonna alkaloid
that acts like atropine. Like the other anticholinergics, this drug acts on the muscarinic
receptors, and in this case, blocks all five subtypes. It is also effective in humans at a
dosage that does not produce sedation, indicating that its actions may be specific within
the vestibular nuclei.(24) The mechanism of action is thought to be associated with
inhibition of vestibular input into the CNS which thus inhibits the vomiting reflex. It
may also directly act on the vomiting center in the reticular formation of the
brainstem.(1)
Scopolamine has been shown to be
effective in all the classic cases of motion sickness, involving car, air, train, and sea
travel, as well as exposure to virtual reality systems.(25) It is currently available for
prescription in two forms: a transdermal patch and a low dose tablet. Each dosage form has
its respective benefits and disadvantages which warrant consideration when evaluating the
needs of any particular patient.
The scopolamine patch, (Transderm
Scop, Novartis Pharmaceuticals) is attached to the skin behind the ear in a hairless area
and delivers 0.5 mg of scopolamine at a fairly consistent rate over 3 days. This makes the
patch useful for long exposures to motion sickness, such as a prolonged sea voyage since
the patient need not remember to take the shorter-acting tablets.
The patch must be applied well in
advance, however, since an effective drug concentration is not achieved until 6 to 8 hours
after application. This delay can be reduced to an hour or less by simultaneously
administering a single dose of oral or buccal scopolamine.(26)
Large variations in urinary excretion
rates of the drug from patch-wearers, in absorption of scopolamine through the skin, and
in symptom alleviation efficacy have been reported.(27, 28) Variable absorption and
possible underdosage of large patients may have contributed to the report that topical
scopolamine is effective in only 50% to 74% of users.(27) Also due to the fixed dosage,
the patch may not be suitable for children or other small patients.(29)
Common side effects of topical
scopolamine include dry mouth (affecting about 2/3 of people) and drowsiness (affect less
than 1/3). (30)
Low dose scopolamine tablets,
(Scopace, Hope Pharmaceuticals), are also available. These are formulated with 0.4 mg of
scopolamine per tablet, and the prescribed dosage is one to two tablets every 8 hours as
needed. Although scopolamine in tablet form is readily absorbed from the GI tract (9), it
must be taken 1 hour before exposure to motion to reach an effective concentration. The
dosing flexibility provided by the tablet makes this form well suited to shorter outings
such as day fishing, car rides, or plane trips.
The oral route offers certain
advantages over the scopolamine topical patch. In a study conducted for NASA, oral
scopolamine was twice as effective as the topical form in preventing motion sickness
symptoms. (31) Another study showed that motion-induced symptoms decreased 75% with oral
scopolamine compared to 63% with the patch variety.(32) This may be due to greater
consistency in dosage with the oral delivery system.
Another advantage of tablet form is
cost. One dose of scopolamine tablet costs less than 10% of the cost of the patch (33).
Like the patch, the standard dosage of
oral scopolamine also produces some dry mouth and drowsiness. Performance side effects,
however, reportedly occur less frequently with the oral form, however. These include
decrements in tasks involving continuous attention or performance, memorizing new
information, and self-rated feelings of alertness and sociability.(34) Again, this may be
due to the dosing flexibility of the tablet formulation, meaning practitioners can
prescribe the lowest dosage needed to achieve the needed travel comfort.
Although some drowsiness may be a
welcome side effect for travelers who are not operating a vehicle or equipment, this and
other performance side effects of scopolamine can be eliminated by adding 5 to 10 mg of
the sympathomimetic medication d-amphetamine (Dexedrine). (35, 36) The drowsiness produced
by scopolamine and the excitement produced by d-amphetamine effectively cancel each other.
This combination also produces the fastest rate of habituation in motion sickness, but
also leads to increased dry mouth symptoms. (36)
d-Amphetamine and Ephedrine
Because the sympathomimetics, such as
d-amphetamine and ephedrine, increase the release of norepinephrine into the CNS, they
appear to counter the increased activity of acetylcholine-sensitive neurons stimulated by
vestibular activation. (36) d-Amphetamine has been shown to protect against motion
sickness when used alone and to act synergistically when combined with scopolamine or
promethazine.(36) It reduces the sleepiness and performance decrement produced by
scopolamine. The routine use of this controlled drug is unjustified, however, considering
its addiction potential.
Ephedrine, which is not a controlled
drug, could be used instead, although in combination with the anticholinergics, it is much
less effective than d-amphetamine, and its usefulness is questionable based on available
laboratory studies.(37)
Promethazine
In the typical 25 mg oral dose,
promethazine (Phenergan), which is an antihistamine, is slightly less effective than 0.6
mg scopolamine at preventing motion sickness.(9) Promethazine is also the only
phenothiazine that is effective against motion sickness, perhaps because it reportedly has
the strongest central anticholinergic action among this class of drugs.(18)
The onset of effectiveness occurs at 2
hours and its duration ranges from reported 6 hours (9) to as long as 18 hours (28). Side
effects include significant drowsiness, but less dry mouth and dizziness than occurs with
scopolamine. Like scopolamine, adding d-amphetamine or ephedrine to the promethazine
regimen can reduce drowsiness. (35)
SUMMARY
Although the precise etiology of
motion sickness is still unclear, several effective treatments are available to prevent
its symptoms. Numerous clinical trials support the anticholinergic drug scopolamine as the
most effective treatment to prevent motion sickness. This prescription medication,
available in both tablet and topical form, is particularly useful for people who suffer
moderate to severe symptoms. The shorter-acting (8-hour) tablet allows one to control the
precise dose of scopolamine received and should be taken one hour before travel. The
scopolamine patch dispenses the medication over 72 hours and is convenient for long
exposures. However, variable skin absorption and a fixed patch dosage that may not be
suitable for all patients results in reduced efficacy and increased incidence of side
effects compared with scopolamine tablets.
Another prescription medication, the
sympathomimetic drug d-amphetamine, has also been shown to be very effective against for
moderate-to-severe motion sickness; however, its addiction potential makes routine use
unacceptable.
For more mild cases of motion
sickness, over-the-counter remedies have been proven useful. Most of these medications are
antihistamines, and dimenhydrinate appears to be the most effective of this class. The use
of nonpharmacologic remedies, such as ingesting ginger supplements and applying
acupressure to the wrists, is supported by anecdotal reports and awaits confirmation with
controlled clinical studies.
REFERENCES
- Murray JB, Psychophysiological aspects
of motion sickness. Perceptual and Motor Skills 85:1163-1167, 1997.
- Kozarsky PE. Prevention of common
travel ailments. Infect Dis Clin North Am 12:305-324, 1998.
- Grunfeld E, Gresty E. Relationship
between MS, migraine, and menstruation in crew members of a round the world yacht race.
Brain Res Bull 47:433-436, 1998.
- Kennedy RS, Lanham SD, Massey CJ,
Drexler JM, Lilienthal MG. Gender differences in simulator sickness incidence:
implications for military virtual reality systems. SAFE J 25:69-76, 1995.
- Reason JT, Brand JJ. Motion sickness.
London, Academic Press, 1975.
- Oman CM. Motion sickness: a synthesis
and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 68:294-303, 1990.
- Mittelstaedt H. Somatic graviception.
Biol Psychol 42:53-74, 1996.
- Kohl R, Homick JL. Motion sickness: a
modulatory role or the central cholinergic nervous system. Neuroscience and Biobehavioral
Review 7:73-75, 1983.
- Wood CD. Pharmacological
countermeasures against motion sickness. In Crampton GH, ed. Motion and Space Sickness.
CRC Press, Boca Raton, 1990, p. 344.
- Vickers, AJ. Can acupuncture have
specific effects on health? A systematic review of acupuncture antiemesis trials. JR Soc
Med 89: 303-311, 1996.
- Bruce, DG, Golding JF, Hockenhull N. et
al. Acupressure and motion sickness. Aviat Space Environ Med 61: 361-365, 1990.
- Warwick-Evans LA, Masters IJ, Redstone
SB. A double blind placebo controlled evaluation of acupressure in the treatment of MS.
Aviat Space Environ Med 62:776-778, 1991.
- Hu S, Stern RM, Koch KL. Electrical
acustimulation relieves vection-induced motion sickness. Gastroenterology
1992;102:1854-1858.
- Bertolucci LE, Didario B. Efficacy of
portable acustimulation device in controlling seasickness. Aviat Space Environ Med
66:1155-1158, 1995.
- Jozsvai EE, Pigaeu RA. The effect of
autogenic training and biofeedback on motion sickness tolerance. Aviat Space Environ Med
67:963-968, 1996.
- Dobie TG, May JG. Cognitive behavioral
management of motion sickness. Aviation, space, and Environmental Medicine. October
1994;C1-C20.
- Vente PEM, Bos JE, de Wit G. Motion
sickness amelioration induced by prism spectacles. Brain Res Bull 47:503-505 1988.
- Wood CD. Antimotion sickness and
antiemetic drugs. Drugs 17:471-479, 1979.
- Kohl RL, Calkins DS, Mandell AJ.
Arousal and stability: the effects of five new sympathomimetic drugs suggest a new
principle for the prevention of space motion sickness. Aviat Space Environ Med 57:137-143,
1986.
- Wood CD, Graybiel A. A theory of MS
based on pharmacological reactions. Clin Pharmacol Ther 11:621-629, 1970.
- Kohl R, Homick JL. Motion sickness: a
modulatory role or the central cholinergic nervous system. Neuroscience and Biobehavioral
Review 7:73-75, 1983.
- Weinstein SE, Stern RM. Comparison of
Marezine and Dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med
68:890-894, 1997.
- Muth ER, Jokerst M, Stern RM, Koch KL.
Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced MS.
Aviat Space Environ Med 66:1041-1045, 1995.
- Yates BJ, Miller AD, Lucot JB.
Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull
47:395-406, 1998.
- Regan EC, Ramsey AD. The efficacy of
hyoscine hydrobromide in reducing side effects induced during immersion in virtual
reality. Aviat Space Environ Med 67:222-226, 1996.
- Golding JF, Gosden E, Gerrell J.
Scopolamine blood levels following buccal versus ingested tablets. Aviat Space Environ Med
62:521-526, 1991.
- Doweck I, et al. Rate of absorption of
scopolamine after application of scopoderm-TTS. Aviation, Space, and Environmental
Medicine. May 1994;A24.
- Stott JRR. Management of acute and
chronic motion sickness. In Motion sickness: Significance in aerospace operations and
prophylaxis. Nato-Agard, France, 1991, p.175.
- Klein BL. Ashenburg CA, Reed MD.
Transdermal scopolamine intoxication in a child. Pediatr Emergency Care 1:208, 1985.
- Prescibing Information. CIBA
Pharmaceuticals.
- Wood MJ, Wood CD, Stewart JJ, Manno BR,
Mimms BE. Comparison of dosage routes for antimotion sickness drugs. Aviation, Space, and
Environmental Medicine. May 1987, p. 504
- Graybiel A, et al. Prevention of
experimental motion sickness by scopolamine absorbed through the skin. Aviation, Space,
and Environmental Medicine. 47:1096, 1976.
- 1998 Redbook. Medical Economics Co.
Oradell, NJ.
- Parrott AC. The effects of transdermal
scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon
psychological performance. Psychopharmacology. 1986;89:347-354.
- Parrott AC. Transdermal scopolamine: a
review of its effects upon motion sickness, psychological performance, and physiological
functioning. Aviat Space Environ Med 1989;60: 1-9.
- Wood CD, Manno JE, Manno BR, Odenheimer
RC, Bairnsfather LE. The effect of antimotion sickness drugs on habituation to motion.
Aviat Space Environ Med 57:539-542, 1986.
- Tokola O, Latinen LA, Aho J, Gothoni
G, Vapaatolo H. Drug treatment of motion sickness: scopolamine alone and combined with
ephedrine in real and simulated situations. Aviat Space Environ Med 55:636-641, 1984.
|